Platelets As a Novel Source of Gremlin-1: Implications for Thromboinflammation
Overview
Hematology
Authors
Affiliations
Platelets mediating haemostasis-thrombosis are central players in coronary artery disease (CAD). We characterised platelets as a novel source of Gremlin-1. Platelets express Gremlin-1 like inflammatory and endothelial cells. Gremlin-1 co-localised with P-selectin containing randomly distributed α-granules under resting state, which were peripheralised following platelet activation or adhesion over fibrinogen-coated surface. Gremlin-1 release upon activation with ADP, CRP, and TRAP was detected as enhanced surface expression; also in activated platelet supernatant as detected by Western Blot following CRP activation and by ELISA upon activation with ADP, CRP, PAR-1, and PAR4 agonist. Recombinant (rh)Gremlin-1 synergistically enhanced CRP-triggered intracellular calcium mobilisation, ADP-TRAP induced platelet activation, aggregation, and thrombin-activation triggered apoptosis; also thrombus formation ex vivo. Intracellular localisation of macrophage migration inhibitory factor (MIF) and Gremlin-1 a high-affinity binding partner and functional antagonist of MIF were found in intracoronary thrombus sections from acute coronary syndrome (ACS) patients and showed moderate overlap in α-granules of platelets. Intra-platelet Gremlin-1 levels were significantly decreased in ACS patients as compared to stable CAD (n=235). rhGremlin-1 also counteracted the anti-apoptotic and anti-thrombotic effects of rhMIF on platelets. Platelet-derived-Gremlin-1 prompted monocyte migration, facilitated adhesion under static and dynamic arterial flow conditions to collagen-adherent activated platelets; supported monocyte survival against BH-3-mimetic-induced apoptosis and macrophage differentiation in monocyte-platelet co-culture system, which were counteracted upon Gremlin-1 neutralisation. Thus platelet derived Gremlin-1 might contribute to the elevated circulating levels of Gremlin-1 in ACS and serve as a thrombo-inflammatory mediator in cardiovascular pathophysiologies.
Cui P, Cheng T, Yan H, Xu D, Ren G, Ma S Int J Gen Med. 2025; 18:867-880.
PMID: 39990294 PMC: 11847414. DOI: 10.2147/IJGM.S509546.
Liu S, Liu J, Cheng X, Fang D, Chen X, Ding X J Inflamm Res. 2024; 17:7607-7617.
PMID: 39464342 PMC: 11512772. DOI: 10.2147/JIR.S477262.
Evaluation of Gremlin-1 as a therapeutic target in metabolic dysfunction-associated steatohepatitis.
Horn P, Norlin J, Almholt K, Viuff B, Galsgaard E, Hald A Elife. 2024; 13.
PMID: 39361025 PMC: 11449483. DOI: 10.7554/eLife.95185.
Immunothrombosis: A bibliometric analysis from 2003 to 2023.
Hou M, Wu J, Li J, Zhang M, Yin H, Chen J Medicine (Baltimore). 2024; 103(37):e39566.
PMID: 39287275 PMC: 11404911. DOI: 10.1097/MD.0000000000039566.
Valenzuela C, Quintanilla R, Olate-Briones A, Venturini W, Mancilla D, Cayo A Int J Mol Sci. 2019; 20(21).
PMID: 31653055 PMC: 6862446. DOI: 10.3390/ijms20215292.